NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,465.43 mln
Float26.73 mln
Earnings Date08/10/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
636
Transformational upside
Relative Strength
18
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-60.40
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Praxis Precision Medicines is a Boston-based drug development company focused on treating brain disorders where nerve activity becomes dangerously unbalanced. The company is advancing several treatments for conditions such as epilepsy and essential tremor, with multiple drug candidates currently in late-stage clinical trials and others awaiting regulatory approval. Praxis works across two development platforms ? one focused on oral small molecule drugs and another on genetic medicine ? and maintains research partnerships with RogCon and Ionis Pharmaceuticals. Founded in 2015, the company also has a pipeline of earlier-stage programs targeting rare genetic conditions affecting brain function.
